Literature DB >> 28862638

Microglia in Alzheimer's disease.

Heela Sarlus1,2, Michael T Heneka1,2,3.   

Abstract

Microglia are brain-resident myeloid cells that mediate key functions to support the CNS. Microglia express a wide range of receptors that act as molecular sensors, which recognize exogenous or endogenous CNS insults and initiate an immune response. In addition to their classical immune cell function, microglia act as guardians of the brain by promoting phagocytic clearance and providing trophic support to ensure tissue repair and maintain cerebral homeostasis. Conditions associated with loss of homeostasis or tissue changes induce several dynamic microglial processes, including changes of cellular morphology, surface phenotype, secretory mediators, and proliferative responses (referred to as an "activated state"). Activated microglia represent a common pathological feature of several neurodegenerative diseases, including Alzheimer's disease (AD). Cumulative evidence suggests that microglial inflammatory activity in AD is increased while microglial-mediated clearance mechanisms are compromised. Microglia are perpetually engaged in a mutual interaction with the surrounding environment in CNS; thus, diverse microglial reactions at different disease stages may open new avenues for therapeutic intervention and modification of inflammatory activities. In this Review, the role of microglia in the pathogenesis of AD and the modulation of microglia activity as a therapeutic modality will be discussed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28862638      PMCID: PMC5669553          DOI: 10.1172/JCI90606

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  158 in total

1.  Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus.

Authors:  Karin Boekhoorn; Marian Joels; Paul J Lucassen
Journal:  Neurobiol Dis       Date:  2006-06-30       Impact factor: 5.996

Review 2.  Innate immunity in Alzheimer's disease.

Authors:  Michael T Heneka; Douglas T Golenbock; Eicke Latz
Journal:  Nat Immunol       Date:  2015-03       Impact factor: 25.606

3.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation.

Authors:  Hirohide Asai; Seiko Ikezu; Satoshi Tsunoda; Maria Medalla; Jennifer Luebke; Tarik Haydar; Benjamin Wolozin; Oleg Butovsky; Sebastian Kügler; Tsuneya Ikezu
Journal:  Nat Neurosci       Date:  2015-10-05       Impact factor: 24.884

4.  The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.

Authors:  Christian Hundhausen; Dominika Misztela; Theo A Berkhout; Neil Broadway; Paul Saftig; Karina Reiss; Dieter Hartmann; Falk Fahrenholz; Rolf Postina; Vance Matthews; Karl-Josef Kallen; Stefan Rose-John; Andreas Ludwig
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

5.  Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease.

Authors:  Yukiko Doi; Tetsuya Mizuno; Yuki Maki; Shijie Jin; Hiroyuki Mizoguchi; Masayoshi Ikeyama; Minoru Doi; Makoto Michikawa; Hideyuki Takeuchi; Akio Suzumura
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

6.  Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells.

Authors:  L Taupenot; J Ciesielski-Treska; G Ulrich; S Chasserot-Golaz; D Aunis; M F Bader
Journal:  Neuroscience       Date:  1996-05       Impact factor: 3.590

Review 7.  Complement receptor 1 (CR1) and Alzheimer's disease.

Authors:  Helen Crehan; Patrick Holton; Selina Wray; Jennifer Pocock; Rita Guerreiro; John Hardy
Journal:  Immunobiology       Date:  2011-07-23       Impact factor: 3.144

Review 8.  Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.

Authors:  Frederic Brosseron; Marius Krauthausen; Markus Kummer; Michael T Heneka
Journal:  Mol Neurobiol       Date:  2014-02-25       Impact factor: 5.590

Review 9.  Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.

Authors:  Lidia Bakota; Roland Brandt
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

10.  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.

Authors:  Adrian Olmos-Alonso; Sjoerd T T Schetters; Sarmi Sri; Katharine Askew; Renzo Mancuso; Mariana Vargas-Caballero; Christian Holscher; V Hugh Perry; Diego Gomez-Nicola
Journal:  Brain       Date:  2016-01-08       Impact factor: 13.501

View more
  232 in total

1.  Effects of Microglial Cytokines on Alzheimer's Disease-Related Phenomena.

Authors:  Yan Ji; Xiaowan Wang; Colin Kalicki; Blaise W Menta; Megan Baumgardner; Scott J Koppel; Ian W Weidling; Judit Perez-Ortiz; Heather M Wilkins; Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 2.  The benefits of neuroinflammation for the repair of the injured central nervous system.

Authors:  Heather Y F Yong; Khalil S Rawji; Samira Ghorbani; Mengzhou Xue; V Wee Yong
Journal:  Cell Mol Immunol       Date:  2019-03-15       Impact factor: 11.530

Review 3.  The role of macrophages in the resolution of inflammation.

Authors:  Satoshi Watanabe; Michael Alexander; Alexander V Misharin; G R Scott Budinger
Journal:  J Clin Invest       Date:  2019-05-20       Impact factor: 14.808

4.  Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.

Authors:  Vladimir A Ledov; Marina E Golovina; Anna A Markina; Yuriy A Knirel; Vyacheslav L L'vov; Alexander L Kovalchuk; Petr G Aparin
Journal:  Vaccine       Date:  2019-01-19       Impact factor: 3.641

5.  Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.

Authors:  Michael Ewers; Nicolai Franzmeier; Marc Suárez-Calvet; Estrella Morenas-Rodriguez; Miguel Angel Araque Caballero; Gernot Kleinberger; Laura Piccio; Carlos Cruchaga; Yuetiva Deming; Martin Dichgans; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; Christian Haass
Journal:  Sci Transl Med       Date:  2019-08-28       Impact factor: 17.956

6.  Dexamethasone Induces a Specific Form of Ramified Dysfunctional Microglia.

Authors:  Min-Jung Park; Hyun-Sun Park; Min-Jung You; Jongman Yoo; Seung Hyun Kim; Min-Soo Kwon
Journal:  Mol Neurobiol       Date:  2018-06-09       Impact factor: 5.590

7.  Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-κB pathways.

Authors:  Mengqi Yang; Ruili Dang; Pengfei Xu; Yujin Guo; Wenxiu Han; Dehua Liao; Pei Jiang
Journal:  Psychopharmacology (Berl)       Date:  2018-06-25       Impact factor: 4.530

Review 8.  Microglia and macrophage metabolism in CNS injury and disease: The role of immunometabolism in neurodegeneration and neurotrauma.

Authors:  Nicholas A Devanney; Andrew N Stewart; John C Gensel
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

9.  Pathogenesis of Alzheimer's Disease Examined Using a Modified Puri-Li Model that Incorporates Calcium Ion Homeostasis.

Authors:  R A Thuraisingham
Journal:  J Mol Neurosci       Date:  2018-05-13       Impact factor: 3.444

Review 10.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.